FDA
-
-
-
-
-
-
-
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
-
-
-
-
-
-
-
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
-
-
-
-
-
-
-
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Marker Therapeutics (MRKR) announced pre-clinical data from multiTAA-specific T cell product candidate MT-601
-
-
-
-
-
-
-
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
-
-
-
-
-
-
-
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
-
-
-
-
-
-
-
Marker Therapeutics (MRKR) Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

